Teva Pharmaceutical Industries (TEVA) Inventory Average (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Inventory Average for 18 consecutive years, with $3.2 billion the latest figure, recorded in Q1 2026.

• Quarterly Inventory Average rose 1.61% year-over-year to $3.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.2 billion (up 1.61% YoY) and the FY2025 annual result came in at $3.1 billion, down 11.98% from the prior year.
• Inventory Average retreated to $3.2 billion in Q1 2026 per TEVA's latest filing, from $3.3 billion in the prior quarter.
• Over the last five years, Inventory Average for TEVA reached as high as $4.1 billion in Q2 2023 and fell as low as $3.1 billion in Q1 2025.
• A 5-year average of $3.7 billion and a median of $3.9 billion in 2024 frame the typical range for Inventory Average.
• Annual changes were most pronounced in 2023 — Inventory Average increased 4.94% — and 2025, when it fell 21.53%.
• Year by year, Inventory Average stood at $3.8 billion in 2022, then climbed by 4.94% to $4.0 billion in 2023, then retreated by 13.7% to $3.5 billion in 2024, then fell by 6.66% to $3.3 billion in 2025, then declined by 2.26% to $3.2 billion in 2026.
• According to Business Quant data, Inventory Average over the past three periods registered $3.2 billion, $3.3 billion, and $3.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.